{
    "clinical_study": {
        "@rank": "131398", 
        "arm_group": {
            "arm_group_label": "Study", 
            "arm_group_type": "Experimental", 
            "description": "See intervention description."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the\n      development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco\n      smokers.\n\n      PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell\n      lung cancer in tobacco smokers."
        }, 
        "brief_title": "Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers", 
        "completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy and feasibility of celecoxib for chemoprevention of primary\n           non-small cell lung cancer in high-risk tobacco smokers.\n\n        -  Determine the safety and long-term side effects of this drug in this population.\n\n      OUTLINE: Patients receive oral celecoxib twice daily for 6 months.\n\n      Patients are followed at 2 weeks and then at 6 months.\n\n      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 45\n\n          -  Smoked  > 20 pack years\n\n        Exclusion Criteria:\n\n          -  Concurrent use of NSAIDs\n\n          -  Hypersensitivity to celecoxib\n\n          -  Documented allergic-type reaction to sulfonamides\n\n          -  History of allergic reaction, urticaria or asthma to aspirin or other NSAIDs\n\n          -  History of liver dysfunction\n\n          -  Hypertension or cardiac conditions aggravated by fluid retention and edema\n\n          -  Previous history of gastrointestinal ulceration, bleeding, or perforation\n\n          -  Renal dysfunction\n\n          -  End stage respiratory disease\n\n          -  Unstable angina\n\n          -  Other malignancy\n\n          -  Pregnancy\n\n          -  Concurrent use of medication known to alter or be affected by alteration of the\n             hepatic p450 2C9 and 2D6 enzymes\n\n          -  Patents with concurrent medical conditions that may interfere with completion of\n             tests, therapy, or the follow up schedule"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00020878", 
            "org_study_id": "CDR0000068727", 
            "secondary_id": [
                "P30CA016042", 
                "UCLA-0012067", 
                "NCI-G01-1966"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Study", 
            "description": "Dosing will occur for a total of 6 months.  400 mg by mouth twice daily.", 
            "intervention_name": "celecoxib", 
            "intervention_type": "Drug", 
            "other_name": "Celebrex"
        }, 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "non-small cell lung cancer", 
        "lastchanged_date": "July 27, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCLA-0012067"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095-1781"
                }, 
                "name": "Jonsson Comprehensive Cancer Center, UCLA"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Celecoxib for Chemoprevention of Primary Lung Cancer", 
        "overall_official": {
            "affiliation": "Jonsson Comprehensive Cancer Center", 
            "last_name": "Jenny T. Mao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Evaluate the expression of Cox-2 and PGE2 in the lungs of tobacco smokers.", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "Evaluate the capacity for an oral Cox-2 inhibitor (Celecoxib) to suppress the intrapulmonary formation of PGE2", 
                "safety_issue": "Yes", 
                "time_frame": "6 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00020878"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Determine the effects of Cox-2 inhibition on biomarkers of field cancerization on histopathologic abnormalities in patients at risk for primary NSCLC", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "Study the potential role of PGE2 and its regulation by Cox-2 specific inhibitors on antitumor immunity within the lung microenvironment", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }
        ], 
        "source": "Jonsson Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Jonsson Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2001", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Jonsson Comprehensive Cancer Center, UCLA": "34.052 -118.244"
    }
}